NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses (one confirmed) and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.